CLAIRIgen
The Advanced Way
Welcome to CLAIRIgen, the advanced Biotechnology Startup paving the way to the development and manufacturing viral vector platforms for translational research. The company focused on achieving the most efficient development of viral products paired with genome-editing technologies aiming to address unmet needs in CNS diseases. We are a team of passionate scientists, all sharing a vision for success.
Our company focuses on the development of viral vector platforms for modeling and treatment of neurodegenerative diseases with the use of genome and epigenome-editing technologies. We have more than 15 years experience in developing lentiviral, retroviral and adeno-associated vector platforms for gene therapy applications.
Our Technology
CLAIRIgen, based its research and development on proprietary viral platforms for modeling and treatment of neurogenerative syndromes and disorders. The models applied in animals for both generating disease-specific phenotypes and developing treatment regimens. The company pairing next-generation of viral vectors with innovative genome editing tools to develop sophisticated molecular tools for safe and efficient delivery and expression of gene-therapy products targeting CNS diseases and conditions.
